Clinical Evaluation of Gemcitabine in Dogs with Spontaneously Occurring Malignancies

摘要: We conducted a clinical evaluation of gemcitabine in 19 dogs with spontaneously occurring malignancies. The principal objectives this study were to characterize toxicity and seek preliminary evidence antitumor activity administered every 2 weeks (biweekly) as 30-minute IV infusion. A total 64 doses, ranging from 300 mg/m2 675 mg/m2, during the initial 8-week period, an additional 131 doses extended period. cumulative dose for 10 receiving period ranged 1,500 24,300 mg/m2. Clinical was minimal. Cumulative myelosuppression not apparent. Unexplained retinal hemorrhages occurred 1 dog. No complete or partial remissions observed period; however, objective responses Gemcitabine is promising new chemotherapeutic agent that can be used safely cancer. Biweekly administration results minimal acceptable toxicity.